US Branded Generics Market is anticipated to witness a CAGR of ~9-10% by 2027 : A Key Growth Factor is the Patent Expiry of Major Drugs

Branded generics are generic drugs which are given a proprietary market name. It can be developed either by a generic drug company or by the original manufacturer and can be marketed after the patent expiry of the original drug. They are sold by using a brand name instead of a chemical name. An abbreviated new drug application (ANDA) is submitted to the regulatory body for marketing and promoting branded generics and it should be equivalent to the original drug for which the patent is expired.

Various Benefits Offered by Branded Generics Drives its Rapid Adoption in the US Branded Generics Market

Due to the various benefits offered by branded generics, their adoption is projected to grow rapidly in USA. Following are the benefits offered:-
• They are sold as alternatives to brand-name drugs and are less costly.
• For combination drugs, it becomes difficult to remember their generic names. Branded generics can be easily remembered.
• Potentially attract many clients who only prefer branded drugs.
• They provide quality assurance from leading and established companies.

"Branded generics contain only a small percentage of total generic prescriptions in the United States but they are more profitable than unbranded generics."-Tier I Branded Generic Manufacturer, USA

Entrance of India Companies Adds A Competitive and a New Intensity to the Growth of US Branded Generics Market

The market share of the Indian companies in the US branded generics market is estimated to rise significantly in the next five years due to the following factors:
o Higher R&D Spending: Leading Indian companies continue to invest heavily in their R&D activities. Key Indian companies have increased their R&D budgets over the past few years, thus indicating a good launch pipeline of these companies.
o Entry of New Indian companies: The US branded generics market continues to witness the entry of new companies every year, and these companies are poised to further drive the market share of Indian companies in overall ANDA approvals.
o CDMO Entry: Few Indian CDMOs are planning to enter the US branded generics market

Aggressive Growth Strategies Adopted by the Leading Market Players to Establish Their Strong Foothold in the US Branded Generics Market

All the established players operating in the US branded generics market have adopted both organic and inorganic growth strategies such as acquisitions, collaborations, advancements and partnerships to garner a larger market share.

For instance,
• In November 2021, ANI Pharmaceuticals completed the takeover of Novitium Pharma, thus enriching its R&D abilities and scale of generics and CDMO businesses.

The outlook for the US branded generics market looks promising due to the patent expiry of leading drugs, growing number of Indian companies entering the market, comparatively more profitability than unbranded generics, and unfulfilled patient requirements across the therapeutic segments. However, higher costs compared to unbranded generics is one of the major factors which are likely to impact the market growth.

Competitive Landscape Analysis: US Branded Generics Market

The US branded generics market is marked by the presence of some of the well-established and leading market players such as listed below:-
• Teva
• Mylan
• Sandoz
• Sun Pharma
• Hikma, among others.

Get More Detailed Insights on US Branded Generics Market Report @ https://meditechinsights.com/us-branded-generics-market/

Ruta Halde
Associate, Medi-Tech Insights
121/7E Avenue Franklin Roosevelt,
1050 Brussels, Belgium
+32 498 86 80 79
info@meditechinsights.com
https://meditechinsights.com/

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

This release was published on openPR.